resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference

BOSTON, Sept. 24, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the 2018 Cantor Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 3:30 p.m. ET in New York, NY.

A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors. An archived replay will be available for at least 30 days following the presentation.

About resTORbio resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan. resTORbio’s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.

Investor and Media Contact:Jennifer Robinson resTORbio, Inc. 857-772-7029[email protected]  

You May Also Be Interested In

• Solana News: Former Binance and Polygon Executives Join Solana Foundation as Remittix Confirms Its Token Debut
• Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
• Leo Cancer Care Unveils Bold Plans to Improve How Children Experience Radiotherapy, Following World-First Treatments